Alpha 1 Antichymotrypsin [141176-92-3]

Athens Research

Alpha 1 Antichymotrypsin [141176-92-3]

9

Proteolytic Inhibition studies, Alzheimers research, Prostate Cancer Research. In Vitro Diagnostics, Antisera Production

141176-92-3

Research Use Only

≥95% by SDS-PAGE

Alpha-1-antichymotrypsin

Alpha 1-antichymotrypsin (ACT) is an acute-phase plasma glycoprotein encoded by the SERPINA3 gene, primarily produced in the liver. As a member of the serpin superfamily, ACT functions by inhibiting chymotrypsin-like serine proteases, including neutrophil cathepsin G and mast cell chymases. This protective mechanism prevents tissue damage from proteolytic enzymes, particularly in the lower respiratory tract. Normal serum levels range from 25-40mg/dL. During inflammatory processes, ACT concentration increases proportionally to the extent of tissue damage, with levels declining as inflammation resolves. ACT is significantly involved in Alzheimer's disease pathology, where it's overexpressed in astrocytes surrounding amyloid plaques, enhancing amyloid-beta fibrillization and inducing tau hyperphosphorylation. It's also elevated in rheumatoid arthritis, Crohn's disease, ulcerative colitis, and following burn injuries. Clinically, the PSA-ACT complex serves as a valuable biomarker for prostate cancer, indicating tumor mass and clinical staging.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -20°C

41116100